PF-Atlas › Clinical Trials › NCT02805699
A Clinical Evaluation of Baofeikang Granule in Combined Pulmonary Fibrosis and Emphysema Treatment
Baofeikang Granule · Phase 2
Registry ID
NCT02805699
Phase
Phase 2
Status
Unknown
Drug / intervention
Baofeikang Granule
Sponsor
Beijing Municipal Science & Technology Commission
Start
2016-06
Enrollment
120
Locations
2
About this trial
The purpose of this study is to confirm the efficacy and safety of BaofeiKang Granule in the treatment of Combined Pulmonary Fibrosis and Emphysema patients.
Explore related
Medical disclaimer. This page summarizes public trial data for NCT02805699 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.